Skip to content

Study · Not a test of the peptide alone · 2001

2 results

[Effect of transdermal administration of 17-beta estradiol on the release of growth hormone by growth hormone liberating hormone (GH-RH-1-29) in climacteric women before and after treatment].

Vadillo Buenfil M, García De León LE, Caracas Portilla N, González Bárcena D

Ginecologia y obstetricia de Mexico1 Oct 2001

PMID11816525 (opens in a new tab)PepBankPUB-11816525
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome

    In menopausal women, transdermal 17-beta estradiol increased the growth hormone response to a GHRH-1-29 stimulus in proportion to treatment time.

    In plain wordsIn menopausal women, estradiol patches raised the growth hormone response to a GHRH test dose. GHRH was only the test.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH response to GHRH-1-29 stimulus after transdermal estradiol
    Study

    n = 5

    Comparator
    Baseline before estrogen therapy
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    but it does increase the magnitude of response to the stimulus with GH-RH-1-29 proportional to the time of treatment.
    3 context sentences
    Summary · context
    2.74 +/- o 1.21; 3.48 +/- 1.32 (p > 0.05) 4.91 +/- 1.57 (p < 0.05) and 6.04 +/- 1.69 (p < 0.05) (p in relation to baseline) post stimulus with GH-RH-1-29 at baseline 1, 3 and 6 months respectively after transdermal estrogen therapy.
    Summary · context
    We studied 5 patients with a mean age of 51 +/- 4.1 yr. with clinical and biochemical evidence of menopause.
    Summary · context
    We monitored the pulsatility of GH during the first 120 minutes and 3 hours after the administration of the GHRH-1-29-NH2, i.v. bolus (50 micrograms).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome

    In menopausal women, transdermal 17-beta estradiol did not change the pulsatility of growth hormone.

    In plain wordsIn menopausal women, estradiol patches did not change growth hormone pulsatility.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH pulsatility during transdermal estradiol
    Study

    n = 5

    Comparator
    Baseline before estrogen therapy
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    These results demonstrate that transdermal estrogen therapy does not modify the pulsatility of growth hormone
    2 context sentences
    Summary · context
    We studied 5 patients with a mean age of 51 +/- 4.1 yr. with clinical and biochemical evidence of menopause.
    Summary · context
    We monitored the pulsatility of GH during the first 120 minutes and 3 hours after the administration of the GHRH-1-29-NH2, i.v. bolus (50 micrograms).

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.